Journal of Clinical Oncology
Articles in this Issue
Is there an opportunity for checkpoint inhibition in MYC amplified castration resistant prostate cancer?
393 Background: The paradigm of prostate cancer (PCa) management continues to expand with the advent of newer therapies. U...
Incidence of adolescent and young adult renal cell carcinoma in the modern era.
568 Background: The incidence of solid tumors in adolescents and young adults (AYA) has been reported to be increasing, bu...
Tobacco use and survival among veterans with metastatic prostate cancer.
38 Background: Tobacco has been associated with the development of many cancers, but its role in prostate cancer remains u...
Circulating tumor cell detection and prognostic relevance in patients with metastatic genitourinary cancers.
826 Background: Circulating tumor cells (CTCs) are detectable and quantifiable in the peripheral blood of patients (pts) w...
Renal outcomes following <sup>177</sup> Lu-PSMA-617 (LuPSMA) in patients with metastatic castration-resistant prostate cancer (MCRPC).
138 Background: LuPSMA is a PSMA-targeted radiopharmaceutical used to treat mCRPC that may impair kidney function, due to...
Outcomes in participants (pts) with bacillus Calmette-Guérin (BCG)–unresponsive high-risk non–muscle-invasive bladder cancer (NMIBC) who underwent radical cystectomy (RC) after pembrolizumab (pembro): KEYNOTE-057 cohort A post hoc analysis.
745 Background: Based on results from cohort A of the phase 2 KEYNOTE-057 trial (NCT02625961), pembro monotherapy is a bla...
Intravesical T3011, an IL-12/anti-PD-1 armed oncolytic HSV-1, in BCG-naïve high-risk NMIBC: A phase IIa trial.
762 Background: Intravesical BCG is the standard of care for BCG-naïve high-risk non-muscle-invasive bladder cancer (NMIBC...
Clinical implications of prostate specific antigen (PSA) flare and response dynamics in TALAPRO-2: A post-hoc analysis.
168 Background: In the phase 3 TALAPRO-2 study, talazoparib (TALA) + enzalutamide (ENZA) significantly improved radiograph...
Impact of hospitalizations on health-related quality of life and overall survival in metastatic castration-sensitive prostate cancer: Insights from the ARANOTE trial.
53 Background: The impact of hospitalizations on health-related quality of life (HRQoL) and overall survival (OS) in metas...
Treatment and outcomes among patients with metastatic castrate resistant prostate cancer with an AR gene alteration: Analysis from the Kaiser Permanente Northern California Healthcare System.
91 Background: Androgen gene alterations (mutAR) are a key mechanism of resistance in metastatic castrate-resistant prosta...
Circulating kidney injury marker-1 (KIM-1) in metastatic renal cell carcinoma with divergent histologies (RCCdh): Biomarker analysis of the CAN-I trial.
538 Background: The CAN-I trial was a multi-center single arm phase II trial that evaluated cabozantinib, nivolumab and ip...
Cardiometabolic health’s influence on outcomes in men with localized high-risk prostate cancer (HRPCa) treated with pre-operative ADT ± AR pathway inhibition (ARPI).
225 Background: Cardiometabolic health (CMH) has a complex and divergent association with clinical outcomes in men with pr...
A phase 1/2, open-label, randomized, dose-finding and dose expansion study of gedatolisib in combination with darolutamide in metastatic castration-resistant prostate cancer (mCRPC).
TPS304 Background: Progression to mCRPC occurs in most patients (pts) treated with androgen receptor pathway inhibitors (A...
Trimodal therapy versus radical cystectomy in muscle-invasive bladder cancer: The overlooked influence of informative censoring—A systematic review and meta-analysis.
729 Background: Informative censoring (IC) is a statistical bias that occurs when dropout rates differ between study arms...
Bladder cancer innervation: Does it affect prognosis?
855 Background: Numerous studies have lately demonstrated the potentially important role of autonomic nerves in tumorigene...
Nezastomig (anti-PSMA×CD28) with or without cemiplimab (anti–PD-1) in patients with metastatic castration-resistant prostate cancer (mCRPC) or metastatic clear cell renal cell carcinoma (mccRCC): A phase 1/2 study.
TPS296 Background: Advanced mCRPC and mccRCC are urologic malignancies associated with poor prognoses, presenting an unmet...
The practice of active surveillance for prostate cancer: Trends, variation, and quality within a large national health system.
347 Background: Active surveillance (AS) is broadly endorsed as preferred management for low-grade prostate cancer, but fe...
FORAGER-2: A randomized phase 3 study evaluating the efficacy and safety of vepugratinib combined with enfortumab vedotin and pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma with an FGFR3 genetic alteration.
TPS895 Background: Treatment with enfortumab vedotin (EV)/pembrolizumab (P) has significantly improved clinical outcomes f...
Genomic analyses of bilateral testicular germ cell cancers (BITCOIN study) from the Italian Germ Cell Cancer Group (IGG).
617 Background: Despite Testicular Germ Cell Tumors (TGCT) being the most common malignancy in young men aged 15 to 44 yea...
Real-world use and effectiveness of first-line enfortumab vedotin (EV) with pembrolizumab (P) in patients with advanced urothelial carcinoma (aUC).
692 Background: EV+P significantly improved overall survival (OS) compared with platinum-based chemotherapy in the EV-302...
Establishment and characterization of a panel of prostate adenocarcinoma XPDX models representing naïve, chemotherapy- and radiotherapy-resistant patient populations.
251 Background: Preclinical models of prostate adenocarcinoma (PRAD) are challenging to establish and maintain. We previou...
Bladder cancer (BC) screening in un-affected Caucasian ancestry family members of patients who tested positive for germline homologous recombination repair (gHRR) and mismatch repair (gMMR) variants.
TPS879 Background: According to GLOBOCAN, in 2020 there were 573 000 new BC cases and predictions show a significant incre...
Redefining multimodal treatment in high-volume metastatic hormone-sensitive prostate cancer: Prospective evidence for robot-assisted cytoreductive prostatectomy following triplet systemic therapy.
193 Background: For newly diagnosed high-volume metastatic hormone-sensitive prostate cancer (mHSPC), front-line therapy t...
Real-world outcomes of radium-223 in the FRONTIER study: Impact of prior up-front therapy in mCRPC.
63 Background: The role of Radium-223 (Ra-223) after up-front therapies for metastatic castration-sensitive prostate cance...
A liquid biopsy targeted proteomic assay to predict outcomes in castration resistant prostate cancer patients treated with 177Lu-PSMA-617.
250 Background: Plasma-based targeted proteomics is an emerging area with great potential to aid in cancer diagnostics via...